Model of multiple myeloma treatment with Dara (control, u), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression.

The cell populations are healthy marrow cells (A), CD38+ cancer and CD38− cancer , and all arrows represent movement of cells between populations or states. Three drug actions are included (green arrows): cell mortality and loss of CD38 expression in the CD38+ cancer cell...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
מחבר ראשי:	James G. Lefevre (11303976) (author)
מחברים אחרים:	Brodie A. J. Lawson (8771843) (author), Pamela M. Burrage (16938568) (author), Diane M. Donovan (22033185) (author), Kevin Burrage (21168) (author)
יצא לאור:	2025
נושאים:	Biophysics Biochemistry Medicine Genetics Pharmacology Biotechnology Cancer Hematology Infectious Diseases Biological Sciences not elsewhere classified target drug effects plasma cell cancer monoclonal antibody daratumumab target drug effect healthy cells due cd38 expression switches optimal treatment regime drug resistance mechanisms healthy cells drug action cd38 expression cancer cells optimal treatment added mechanisms optimal control myeloma cells leading treatment express cd38 daratumumab treatment cd38 receptor proposed mechanism ode model lower fitness indirect effect identified within highly overexpressed general increase direct effect bone marrow
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

תיאור
סיכום:	<p>The cell populations are healthy marrow cells (<i>A</i>), CD38+ cancer and CD38− cancer , and all arrows represent movement of cells between populations or states. Three drug actions are included (green arrows): cell mortality and loss of CD38 expression in the CD38+ cancer cells, and off-target cell mortality in healthy cells within the compartment.</p>

Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression.

פריטים דומים